Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2021-03-12

FDA Approved: BUPROPION HYDROCHLORIDE SR — Supplemental Application (Solco Healthcare US LLC)

View source ↗

Summary

The FDA approved a supplemental application for a generic version of Bupropion hydrochloride sustained-release from Solco Healthcare US LLC under ANDA 202304.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Bupropion hydrochloride sustained-release (Bupropion hydrochloride)

Snippet

SUPPL AP for BUPROPION HYDROCHLORIDE SR (BUPROPION HYDROCHLORIDE)